ArticleJournal of experimental & clinical cancer research : CR2014
Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.
Article in Journal of experimental & clinical cancer research : CR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Prognostic Significance and Functional Mechanism of UTS2 in Glioblastoma Multiforme.Current cancer drug targets · 2025Article
- Targeting the Urotensin II/UT G Protein-Coupled Receptor to Counteract Angiogenesis and Mesenchymal Hypoxia/Necrosis in Glioblastoma.Frontiers in cell and developmental biology · 2021Article
- The Effect of Local Renin Angiotensin System in the Common Types of Cancer.Frontiers in endocrinology · 2021Review
- The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure.Heliyon · 2020Article
- Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?Journal of endocrinological investigation · 2019Article
- Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells.Journal of oncology · 2019Article
- Urotensin II receptor as a potential biomarker for the prognosis of hepatocellular carcinoma patients.Oncology letters · 2017Article
- Orexin System: The Key for a Healthy Life.Frontiers in physiology · 2017Review
- Exercise Influence on Hippocampal Function: Possible Involvement of Orexin-A.Frontiers in physiology · 2017Review
- The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.Frontiers in endocrinology · 2017Review
- Neuroprotective Effects of Physical Activity: Evidence from Human and Animal Studies.Frontiers in neurology · 2017Review
- Obesity and brain illness: from cognitive and psychological evidences to obesity paradox.Diabetes, metabolic syndrome and obesity : targets and therapy · 2017Review
- Increased expression of urotensin II is associated with poor prognosis in hepatocellular carcinoma.Oncology letters · 2016Article
- Chemotactic G protein-coupled receptors control cell migration by repressing autophagosome biogenesis.Autophagy · 2016Article
- From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples.Frontiers in pharmacology · 2016Article
- Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer.Future oncology (London, England) · 2015Article
- Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma.Oncogene · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon Muscle Invasive Bladder Transitional Cancer (NMIBC) and Muscle Invasive Bladder Transitional Cancer (MIBC)/invasive have different gene profile and clinical course. NMIBC prognosis is not completely predictable, since the relapse rate is higher than 20%, even in the form of MIBC. The aim of this study is to evaluate if UTR expression can discriminate between NMIBC and MIBC and predict the risk of relapses in NMIBCs.
methodsWe have investigated upon urotensin-II (UII) receptor (UTR) expression in vivo in 159 patients affected by NMIBC. The biological role of UTR was also investigated in vitro. UTR expression was evaluated in a tissue-micro-array, consisting of normal, NMIBC and invasive bTCC samples.
resultsUTR discriminated between NMIBC and MIBC and showed a significant correlation between low UTR expression and shorter disease free survival in NMIBC. The superagonist UPG84 induced growth suppression at nM concentrations on 3/4 cell lines. Bladder cancer cell treatment with the antagonist urantide or the knock-down of UTR with a specific shRNA significantly blocked both the motility and invasion of bladder cancer cells.
conclusionsThe evaluation of UTR expression can discriminate between NMIBC at high and low risk of relapse. Moreover, our data suggest that UTR is involved in the regulation of motility, invasion and proliferation of bladder cancer cells. High UTR expression is an independent prognostic factor of good prognosis for NMIBC regulating motility and invasion of bladder cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.